A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Jacobs acknowledged that Novavax does not have the market leverage and scale of French drugmaker Sanofi, with which it signed ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...

Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...

Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the country. The latest ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...

PARIS — Israel and France squared off in a soccer match at Paris' Stade de France on Thursday night as hundreds of protesters gathered nearby amid heightened tensions in Europe over Israel’s ...